Lilly Medical US’ Post

Please read our paper just published in JITC. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. https://lnkd.in/eXwDBGZc  https://lnkd.in/ecqjqda3

With the advancement of two clinical trials treating KRAS G12D mutated cancers and the initiation of GLP toxicology studies for QTX3544, a G12V-preferring multi-#KRAS inhibitor, we aim to address the significant unmet need for patients with KRAS-mutated cancer beyond G12C.

Excited to share we’ve dosed our first patient in the Phase 1/1b clinical trial of QTX3046, an oral, dual (OFF/ON)-state KRASG12D-selective inhibitor and initiated patient dosing in the combination portion of the ongoing Phase 1 trial assessing QTX3034, a G12D-preferring multi-#KRAS inhibitor. Both are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more: https://bit.ly/4ciYUZ0

If you are attending the European Society for Medical Oncology Annual Meeting in Barcelona, Spain this week, be sure to check out the Proffered paper session happening this afternoon: GU tumors, prostate. Here, data on the ability of Veracyte, Inc.'s #Decipher Prostate to predict survival benefit from docetaxel at the start of ADT for advanced #ProstateCancer patients enrolled in the STAMPEDE trial will be presented. #ESMO24

We extend our gratitude to Igor Puzanov, MD, of Roswell Park Comprehensive Cancer Center for his insightful review of our clinical data from the Phase 1/1b trial evaluating WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the promise of our INDUKINE hypothesis, which suggests that potent cytokine-based immunotherapies can address difficult-to-treat tumors while minimizing the typical toxicities associated with Interleukin-2 (IL-2) therapy. Watch the MedPage Today story here: https://lnkd.in/e5SQKBVF Read more about WTX-124: https://lnkd.in/eEwKG2p4 #HOWL #ImmunoOncology #Cytokines #Cancer #Biotech #ASCO #ASCO24

Read about the rationale and design of the ongoing INSIGHT trial, which is investigating ripretinib versus sunitinib for certain patients with advanced gastrointestinal stromal tumor. Discover further details of the paper here:https://hubs.ly/Q02NM5260

We’re investigating a #Nectin4 targeted antibody-drug conjugate (ADC) in patients with advanced or metastatic #UrothelialCarcinoma or other solid tumors.    Learn more about the Phase 1 trial here: https://e.lilly/3VR2ns8

High Tumor Burden: The Kryptonite of CAR T-Cell Therapy? This review focuses on linking the efficacy and safety of CAR T-cell therapy with tumor burden by JAMA

🎙 Tune in to OncologyTube.com to hear our Vice President of Clinical Development, Kellogg Parsons, MD, MHS, FACS at #SABC23, overview the applications of our lead investigational #ADC therapeutic, MBRC- 101, which targets EphA5 in advanced #solidtumors and shows promise in various cancers, including #breastcancer subtypes. Listen here: https://lnkd.in/gckw7gqW  

Encouraging activity in CCNE activated ovarian and endometrial cancers